KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Gross Margin (2016 - 2025)

Nektar Therapeutics has reported Gross Margin over the past 16 years, most recently at 68.61% for Q4 2025.

  • Quarterly results put Gross Margin at 68.61% for Q4 2025, up 3489.0% from a year ago — trailing twelve months through Dec 2025 was 50.27% (down 430.0% YoY), and the annual figure for FY2025 was 19.02%, down 3826.0%.
  • Gross Margin for Q4 2025 was 68.61% at Nektar Therapeutics, up from 12.66% in the prior quarter.
  • Over the last five years, Gross Margin for NKTR hit a ceiling of 100.0% in Q1 2025 and a floor of 7.62% in Q2 2025.
  • Median Gross Margin over the past 5 years was 70.15% (2022), compared with a mean of 62.83%.
  • Peak annual rise in Gross Margin hit 5178bps in 2025, while the deepest fall reached -6895bps in 2025.
  • Nektar Therapeutics' Gross Margin stood at 75.36% in 2021, then decreased by -5bps to 71.7% in 2022, then dropped by -22bps to 55.78% in 2023, then plummeted by -40bps to 33.72% in 2024, then surged by 103bps to 68.61% in 2025.
  • The last three reported values for Gross Margin were 68.61% (Q4 2025), 12.66% (Q3 2025), and 7.62% (Q2 2025) per Business Quant data.